infectious diseases

News

Basilea preps key US filing for MRSA antibiotic ceftobiprole

Basilea Pharmaceutica may finally be able to bring its antibiotic ceftobiprole to the US market – 13 years after its first attempt was turned down – thanks to a new phase 3 clinical trial.<

News

GSK pledges £1bn drive for infectious disease R&D

GSK will invest around £1 billion ($1.2 billion) over a 10-year period to speed up R&D on infectious diseases that mainly impact lower-income countries.

Events

Partner Content

2nd Annual mRNA-Based Therapeutics Summit Europe

Accelerating platforms for mRNA vaccines

News

Parasitic biting insect on background of epidermis detail. Disgusting carrier of encephalitis, Lyme disease or babesiosis infections. Tick-borne diseases

Readout sets up phase 3 for Valneva/Pfizer's Lyme disease ja...

There's only one vaccine candidate for tick-borne infection Lyme disease in clinical development – Valneva and Pfizer's VLA15 – and it has just moved another step closer to being available.

News

Cidara and Mundipharma prep filings for antifungal rezafungi...

Mundipharma and Cidara Therapeutics have reported the results of a phase 3 trial of their new once-weekly antifungal rezafungin, setting up regulatory filings in t

Events